Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 12,643 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period A Clear all

Conditions: Hypertension
Interventions: Metoprolol succinate, Nebivolol, Non-invasive measurement of Cardiac Output (CO), Endothelial cell collection, Microvascular perfusion assessment using Definity; Drug · Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Language Delay, Language Development, Feeding; Difficult, Newborn, Mother-Infant Interaction, Maternal Behavior
Interventions: Oromotor stimulation, Reading curriculum, LENA recording, LENA linguistic feedback, No oromotor stimulation; Behavioral
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 23 Weeks to 30 Weeks
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Healthy Volunteers
Interventions: Lenvatinib; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Hypertension, Cardiovascular Diseases, Vascular Diseases
Interventions: Aerobic Training, Resistance Training; Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 55 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin Aspart, Insulin Lispro; Drug
Lead sponsor: Tulane University Health Sciences Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Generalized Myasthenia Gravis
Interventions: Batoclimab 680 mg SC weekly, Batoclimab 340 mg SC weekly, Matching Placebo SC, Batoclimab 340 mg SC bi-weekly; Drug
Lead sponsor: Immunovant Sciences GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 30
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Carlsbad, California + 27 more

Conditions: Medication Adherence, Medication Nonadherence, Adverse Reaction to Drug
Interventions: Computerized medication delivery unit (Electronic Medication Management Assistant (EMMA); Device
Lead sponsor: University of Pittsburgh; Other
Eligibility: 65 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Advanced Solid Tumor
Interventions: Nemvaleukin alfa, Pembrolizumab; Biological
Lead sponsor: Mural Oncology, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 4
States / cities: Grand Rapids, Michigan • Houston, Texas • West Valley City, Utah + 1 more

Conditions: Postpartum Weight Retention, Overweight and Obesity
Interventions: Early Time-Restricted Eating (eTRE), Control; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hypertension
Interventions: iHealth Wireless Blood Pressure Monitor; Device
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Hyperlipidemia
Interventions: AEGR-733, placebo, AEGR-733 and atorvastatin, AEGR-733 and fenofibrate, AEGR-733 and ezetimibe; Drug
Lead sponsor: Aegerion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 15
States / cities: San Diego, California • Santa Rosa, California • Washington D.C., District of Columbia + 10 more

Conditions: Back Pain
Interventions: Arbaclofen placarbil, 20 mg, Placebo, Arbaclofen placarbil, 30 mg, Arbaclofen placarbil, 40 mg; Drug
Lead sponsor: XenoPort, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 20
States / cities: Litchfield Park, Arizona • Anaheim, California • San Diego, California + 16 more

Conditions: Obesity
Interventions: Eucaloric Feeding Period, Overfeeding Feeding Period, Underfeeding Feeding Period; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 25 Years to 40 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: mCRPC
Interventions: Placebo, Senaparib; Drug
Lead sponsor: Impact Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Binghamton, New York

Conditions: Type 1 Diabetes Mellitus
Interventions: iBOLUSED; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 21 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Nausea and Vomiting, Chemotherapy-Induced
Interventions: Casopitant (GW679769) oral tablets, Warfarin oral tablets; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: Gainesville, Florida • Buffalo, New York

Conditions: Prostate Cancer, Prostate Neoplasm
Interventions: HDR brachytherapy; Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Cancer
Interventions: Not listed
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: Not listed
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 3
States / cities: Fort Lauderdale, Florida • Columbus, Ohio • Nashville, Tennessee

Conditions: Alcohol Use, Underage Drinking, Parenting Intervention, Prevention, Faith-Based, Implementation Science
Interventions: Guiando Buenas Decisiones (GBD); Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 12 Years and older
Enrollment: 440 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Major Depressive Disorder
Interventions: LY2216684, Placebo-matching LY2216684, Placebo-matching alcoholic beverage, Alcoholic beverage; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Glioma of Brain
Interventions: Topotecan; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Hyperopia
Interventions: Acuvue Advance Plus, Acuvue Advance; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 3
States / cities: Winter Park, Florida • New York, New York • Nanticoke, Pennsylvania

Conditions: Gastroparesis
Interventions: Transcutaneous Electroacupuncture, Sham TEA; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: X-linked Adrenoleukodystrophy
Interventions: vitamin D3; Dietary Supplement
Lead sponsor: Stanford University; Other
Eligibility: 18 Months to 25 Years · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Palo Alto, California

Search by objective public record fields.

Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients

Combined Oral Motor Stimulation and Language on Preterm Infant Feeding

Crossover Study to Evaluate the Relative Bioavailability and Palatability of a Lenvatinib Suspension Compared to the Capsule Formulation in Adult Healthy Volunteers

Improving Blood Pressure and Cardiovascular Risk With Resistance Exercise in African Americans

Comparison of Insulins Aspart and Lispro in Insulin Pumps

Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis

Feasibility of Using a Telemedicine Medication Delivery Unit for Older Adults

Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)

Time-restricted Eating for Postpartum Weight Loss

Assessing Blood Pressure Remotely in Childhood Cancer Survivors

Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS

A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms

The Effects of Energy Imbalance on Food Intake Behaviors

Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment

Evaluation of a Simulation-Based Educational Tool for Personalized Feedback in Insulin Therapy Management

A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers

Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy

Met Non Small Cell Cancer Registry (MOMENT)

Parent-Focused Alcohol Prevention Program for Hispanic Families in Faith-Based Settings

A Study of LY2216684 in Healthy Participants

Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma

Pilot Dispensing Evaluation of a Plus Power Lens

Transcutaneous Electroacupuncture for Gastrointestinal Motility Disorders

A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy